Tanios S. Bekaii-Saab, MD, on Next-Generation Sequencing for Gastrointestinal Cancer

Video

The medical oncologist spoke about the need to make next-generation sequencing available to all patients with gastrointestinal cancer.

Next-generation sequencing has revolutionized genomic research, helping oncologists to deliver the proper treatment to the proper target, thereby improving outcomes.

Specifically for patients with gastrointestinal cancers, precision therapy has represented a paradigm shift in the way oncologists approach patient care.

In an interview with CancerNetwork®, Tanios S. Bekaii-Saab, MD, a medical oncologist at the Mayo Clinic in Phoenix, Arizona, discussed why next-generation sequencing is so important for patients with gastrointestinal cancers, as well as the need to make genomic sequencing the standard of care for this entire patient population.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.

Related Videos
Rates of obesity appear to correlate with increasing incidence of cancer in young populations, according to Monique Gary, DO, MSc, FACS.
Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.
It takes a team of physicians from multidisciplinary backgrounds to best manage patients with contralateral breast cancer, according to a Mayo Clinic Expert.
The presence of several risk factors—such as age, race and mutation status—for contralateral breast cancer must be considered when making treatment decisions, according to an expert from the Mayo Clinic.
Recent study findings related to risk factors for developing contralateral breast cancer may better influence treatment decisions between patients and physicians, according to a Mayo Clinic expert.
An expert from the Mayo Clinic discusses findings from a population-based study concerning germline genetic mutations as risk factors of contralateral breast cancer.
Thus far, findings from 2 trials show that treatment with bipolar androgen therapy is associated with several benefits in patients with castration-resistant prostate cancer, according to an expert from Sidney Kimmel Comprehensive Cancer Center.
An expert from the Mayo Clinic explains why he and his colleagues are researching risk factors for contralateral breast cancer in carriers of moderate-risk genes such as ATM, CHEK2, and PALB2.
Investigators have observed that treatment with bipolar androgen therapy has suppressed at least one oncogene in patients with castration-resistant prostate cancer who derived a response to therapy.
Despite the observed disease-free survival benefit associated with pembrolizumab in high-risk kidney cancer after surgery, the European Association of Urology guidelines maintain a weak recommendation for its use.
Related Content
FDA OKs Pembrolizumab/Chemo in HER2- Gastric/GEJ Cancer

FDA OKs Pembrolizumab/Chemo in HER2- Gastric/GEJ Cancer

November 16th 2023
Article

First-line pembrolizumab plus chemotherapy has been approved by the FDA for patients with HER2-negative gastric or gastroesophageal junction adenocarcinoma.

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Oncology On-The-Go Podcast: ASCO 2023 Recap

June 19th 2023
Podcast

Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

FDA Updates Indication for Pembrolizumab in HER2+ Gastric/GEJ Adenocarcinoma

November 9th 2023
Article

Only patients with PD-L1–positive tumors may receive treatment with pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastroesophageal junction adenocarcinoma following the FDA’s amendment.

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC

Oncology Peer Review On-The-Go: Tanios Bekaii-Saab, MD, and Experts Examine Therapy Resistance in CRC

May 24th 2022
Podcast

Tanios Bekaii-Saab, MD, talks with Kristen Ciombor, MD, MSCI, and John Strickler, MD, about targeted therapy resistance, rechallenge, and acquired resistance mutations in colorectal cancer.

CMG901 demonstrated a well-tolerated safety profile in patients with CLDN18.2-positive, advanced gastric/gastroesophageal junction cancer.

CMG901 Shows Potential in CLDN18.2-Positive Advanced Gastric/GEJ Cancer

November 8th 2023
Article

CMG901 demonstrated a well-tolerated safety profile in patients with CLDN18.2-positive, advanced gastric/gastroesophageal junction cancer.

Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.

Domvanalimab Plus Zimberelimab Improve Efficacy in Gastrointestinal Cancers

November 7th 2023
Article

Results from arm A1 of the phase 2 EDGE-Gastric study indicate that patients with gastric, gastroesophageal junction, and esophageal adenocarcinoma experienced improved responses after receiving domvanalimab/zimberelimab.